MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC (clinicaltrials.gov) - Oct 22, 2026 - P2 | N=100 | Not yet recruiting | Sponsor: Peking University People's Hospital
Circulating tumor DNA • New P2 trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1
|